We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
11 own
15 watching
Current Price
$52.23
$1.04
(2.03%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
4,946.27M
52-Week High
66
52-Week Low
34.43
Average Volume
0.15M
Dividend Yield
--
P/E Ratio
--
Market Capitalization4,946.27M
52-Week High66
52-Week Low34.43
Average Volume0.15M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. The company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of central nervous system and other disorders. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
18days ago
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate at two upcoming investor ...
Business Wire
5 months ago
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intra-Cellular Therapies, Inc. (Intra-Cellular or the Company) (NASDAQ: ITCI) for violations of the securities laws. The investigation focuses on whether the...
Zolmax
5 months ago
D. E. Shaw & Co. Inc. purchased a new position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI Get Rating) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 153,587 shares of the biopharmaceutical companys stock, valued at approximately $8,039,000. Other large ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$52.23
$1.04
(2.03%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00